Intervention
Cisplatin
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 507 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownA Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT07680764 · 2026-09-10
RECRUITINGA Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.NCT07559929 · 2026-08-19
RECRUITINGA Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)NCT07642024 · 2026-07-24
RECRUITINGLow-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung CancerNCT07583550 · 2026-07-20
RECRUITINGA Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)NCT07622186 · 2026-07-15
RECRUITINGFutibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerNCT07710885 · 2026-06-24
RECRUITINGBeamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without PembrolizumabNCT07486817 · 2026-06-04
RECRUITINGSCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerNCT07662395 · 2026-05-09
RECRUITINGTrial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural MesotheliomaNCT07234058 · 2026-04-02
RECRUITINGA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)NCT07216703 · 2026-01-19
RECRUITINGA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionNCT07063745 · 2026-01-02
RECRUITINGA Platform Study in Non-Small Cell Lung Cancer (NSCLC)NCT06996782 · 2025-11-24
RECRUITINGOral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung CancerNCT07001618 · 2025-11-17
RECRUITINGStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)NCT07100080 · 2025-11-05
RECRUITINGA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06793215 · 2025-10-24
RECRUITINGA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)NCT07190248 · 2025-10-08
RECRUITINGA Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLCNCT07178795 · 2025-09-29
RECRUITINGIBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung CancerNCT07122687 · 2025-08-26
RECRUITINGA Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsNCT07090499 · 2025-08-20
RECRUITINGA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerNCT07005102 · 2025-08-03
RECRUITINGA Study of LY4175408 in Participants With Advanced CancerNCT07046923 · 2025-07-28
RECRUITINGProspective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLCNCT06745882 · 2025-06-13
RECRUITINGA Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)NCT06952504 · 2025-05-22
RECRUITINGA Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLCNCT06969612 · 2025-05-15
RECRUITINGAdjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World StudyNCT07640048 · 2025-05-04
RECRUITINGA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)NCT06875310 · 2025-04-24
RECRUITINGPhase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）NCT06927986 · 2025-03-30
RECRUITINGStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsNCT06772623 · 2025-03-06
RECRUITINGStudy of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.NCT06431633 · 2025-02-04
RECRUITINGA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647 · 2024-11-27
RECRUITINGPerioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung CancerNCT06659042 · 2024-11-20
RECRUITINGA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 · 2024-10-21
RECRUITINGA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%NCT06561386 · 2024-10-07
RECRUITINGA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06417814 · 2024-10-04
RECRUITINGA Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsNCT06561685 · 2024-09-19
RECRUITINGA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)NCT06452277 · 2024-08-28
RECRUITINGAdebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung CancerNCT06480864 · 2024-08-09
RECRUITINGSafety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCNCT06217757 · 2024-04-18
RECRUITINGStudy to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT06236438 · 2024-04-10
RECRUITINGA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)NCT06312137 · 2024-04-03
RECRUITINGGenomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)NCT06387056 · 2024-04-01
RECRUITINGStudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCNCT06162221 · 2024-01-18
RECRUITINGA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNCT06119581 · 2023-12-21
RECRUITINGA Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal MesotheliomaNCT06057935 · 2023-09-21
RECRUITINGTesting the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerNCT05624996 · 2023-07-12
RECRUITINGA Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationNCT05789082 · 2023-06-20
RECRUITINGPembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)NCT03760575 · 2023-01-10
RECRUITINGA Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.NCT05487391 · 2022-12-08
RECRUITINGAdding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With SurgeryNCT04991025 · 2022-10-19
RECRUITINGStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)NCT05489211 · 2022-09-06
RECRUITINGSKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.NCT05351788 · 2022-05-20
RECRUITINGNeoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerNCT05061550 · 2022-04-14
RECRUITINGUsing ctDNA to Determine Therapies for Lung CancerNCT04966663 · 2022-03-28
RECRUITINGPathological Response After Neoadjuvant Treatment on NSCLCNCT05167487 · 2021-12-13
RECRUITINGAdditional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)NCT05281406 · 2021-11-12
RECRUITINGA Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerNCT05104788 · 2021-10-25
RECRUITINGAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCNCT04585490 · 2021-08-25
RECRUITINGNeoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLCNCT05011487 · 2021-08-13
RECRUITINGAB122 Platform StudyNCT04999761 · 2021-06-01
RECRUITINGPhase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCNCT04686305 · 2021-03-09
RECRUITINGCommon conditions
Non-small Cell Lung Cancer94Carcinoma, Non-Small-Cell Lung34Lung Cancer32Non Small Cell Lung Cancer28Breast Cancer18Small Cell Lung Cancer18NSCLC12Metastatic Breast Cancer10Malignant Pleural Mesothelioma9Non-Small-Cell Lung Carcinoma9Stage IIIA Non-Small Cell Lung Cancer9Triple Negative Breast Cancer9Non-Squamous Non-Small Cell Lung Cancer8Stage III Lung Cancer AJCC v88Stage IIIA Lung Cancer AJCC v88Colorectal Cancer7Small Cell Lung Carcinoma7Head and Neck Cancer6Mesothelioma6Metastatic Non-Small Cell Lung Cancer6Non-small Cell Lung Cancer (NSCLC)6Stage IIIA Lung Non-Small Cell Cancer AJCC v76Stage IIIB Lung Cancer AJCC v86Bladder Cancer5Gastric Cancer5
Leading sponsors
Trial status mix
COMPLETED206
ACTIVE_NOT_RECRUITING73
TERMINATED72
RECRUITING65
UNKNOWN43
WITHDRAWN27
NOT_YET_RECRUITING17
SUSPENDED2
ENROLLING_BY_INVITATION1
NO_LONGER_AVAILABLE1
Phase mix
PHASE2250
PHASE3168
PHASE1121
NA7
PHASE46
EARLY_PHASE13
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.